

RECEIVED  
CENTRAL FAX CENTER

JAN 17 2005

BEST AVAILABLE COPY

Atty Docket No. 19452A-000320US

PTO FAX NO.: 703-872-9306

ATTENTION: Examiner Zara, Jane J.

Group Art Unit 1635

**OFFICIAL COMMUNICATION**  
**FOR THE PERSONAL ATTENTION OF**  
**EXAMINER Zara, Jane J.**

**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents in re Application of MARTH and ELLIES, Application No. 09/856,391, filed January 7, 2002 for USE OF CORE 2 GLCNAC TRANSFERASE INHIBITORS IN TREATING INFLAMMATION are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment

Number of pages being transmitted, including this page: 9

Dated: February 17, 2005

  
Stephanie J. Whitehurst

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: 415-576-0200  
Fax: 415-576-0300

60425272 v1

BEST AVAILABLE COPY

RECEIVED  
CENTRAL FAX CENTER

0002/009

JAN 17 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the United States Patent and Trademark Office,  
Fax No. 1-703-872-9306 on February 17, 2005.

TOWNSEND and TOWNSEND and CROW LLP

By: Stephanie J. Whitehurst

PATENT

Attorney Docket No. 19452A-000320US

Client Ref. No. 3D99-012-3MI

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MARTH and ELLIES

Application No.: 09/856,391

Filed: January 7, 2002

For: USE OF CORE 2 GLCNAC  
TRANSFERASE INHIBITORS IN  
TREATING INFLAMMATION

Customer No.: 20350

Confirmation No. 7913

Examiner: Zara, Jane J.

Technology Center/Art Unit: 1635

AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed November 19, 2004, please enter the  
following amendments and remarks:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this  
paper.

**Remarks/Arguments** begin on page 4 of this paper.